An Early Phase 1 interventional study of Naproxen and Placebo in Osteoarthritis, sponsored by Pfizer. Completed at 1 site in United Kingdom. Open to female participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-03-14.
Sponsored by Pfizer · Early Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing naproxen in Osteoarthritis — none open to participants now, 1 under way, none of them phase 3. Naproxen · Osteoarthritis.
Among the 14 studies testing naproxen in Osteoarthritis, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 1, and was the 9th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.
Browse Osteoarthritis studies →None of the 14 studies testing naproxen in Osteoarthritis is open now. The open studies under Osteoarthritis, anywhere →
Naproxen: first FDA approval 1976 (NAPROSYN). What it is approved for, and how studies give it, is on its page →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 50 Years to 80 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 80 across 2,241 interventional studies indexed under Osteoarthritis.
Median enrollment 103 across the 14 interventional studies. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 9 most frequent:
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
39 studies in Osteoarthritis by Pfizer: 2 open now, 2 under way, 2 of them phase 3. Of 36 finished, 20 (56%) have results posted.
Among the 39 studies in Osteoarthritis by Pfizer, this one is the 30th largest by enrollment of the 37 interventional ones that give a count, is one of 6 that started in 2010, is one of 8 in phase 1, and was the 22nd registered.
Pfizer’s Osteoarthritis studies by the year they started, since 2003.
1 of the studies testing naproxen in Osteoarthritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05430230Northwestern UniversityStudy of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies testing naproxen in Osteoarthritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 39 in Osteoarthritis:
This tab as a report to print or save as PDF → With an account.
The study hypothesis is that the relief of pain in patients with osteoarthritis in the hand can be detected by a form of brain scanning that detects which parts of the brain are activated when pain is felt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Naproxen
Drug: Placebo
500 mg BID 7 days
BID 7 days
Changes in voxel-wise Blood Oxygen Level Dependent (BOLD) signal throughout the brain and changes in pre-defined brain regions of interest.
Time frame: 22 days
Whole brain resting-state distribution of Cerebral Blood Flow
Time frame: 22 days
Psychometric measures of pain, namely Daily Pain Diaries and Present Pain Intensity
Time frame: 22 days
Pain induced by a grip task measured with a Visual Analogue Scale (VAS), the Short-Form McGill Pain Questionnaire and patient-rated wrist/hand evaluation (PRWHE)
Time frame: 22 days
The record gives a start of Jul 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naproxen